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Objectives: It is uncertain whether the treatment of mild gestational diabetes mellitus
(GDM) improves pregnancy outcomes. The aim of this systemic review and meta-analysis
was to investigate the effect of mild GDM treatment on adverse pregnancy outcomes.
Methods: A comprehensive literature search was conducted on the databases of
PubMed, Scopus, and Google Scholar to retrieve studies that compared interventions
for the treatment of mild GDM with usual antenatal care. The fixed/random effects models
were used for the analysis of heterogeneous and non-heterogeneous results. Publication
bias was assessed using the Harbord test. Also, the DerSimonian and Laird, and inverse
variance methods were used to calculate the pooled odds ratio of events. The quality
assessment of the included studies was performed using the Modified Newcastle–Ottawa
Quality Assessment scale and the CONSORT checklist. In addition, the risk of bias was
evaluated using the Cochrane Collaboration’s tool for assessing risk of bias.
Results: The systematic review and meta-analysis involved ten studies consisting of 3317
pregnant women who received treatment for mild GDM and 4407 untreated counterparts.
Accordingly, the treatment of mild GDM significantly reduced the risk of macrosomia
(OR = 0.3; 95%CI = 0.3–0.4), large for gestational age (OR = 0.4; 95%CI = 0.3–0.5),
shoulder dystocia (OR = 0.3; 95%CI = 0.2–0.6), caesarean-section (OR = 0.8; 95%CI =
0.7–0.9), preeclampsia (OR = 0.4; 95%CI = 0.3–0.6), elevated cord C-peptide (OR = 0.7;
95%CI = 0.6–0.9), and respiratory distress syndrome (OR = 0.7; 95%CI = 0.5–0.9)
compared to untreated counterparts. Moreover, the risk of induced labor significantly
increased in the treated group compared to the untreated group (OR = 1.3; 95%CI = 1.0–
1.6). However, no statistically significant difference was observed between the groups in
terms of small for gestational age, hypoglycemia, hyperbilirubinemia, birth trauma,n.org March 2021 | Volume 12 | Article 6400041
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Frontiers in Endocrinology | www.frontiersiadmission to the neonatal intensive care unit, and preterm birth. Sensitivity analysis based
on the exclusion of secondary analysis data was all highly consistent with the main data
analysis.
Conclusion: Treatment of mild GDM reduced the risk of selected important maternal
outcomes including preeclampsia, macrosomia, large for gestational age, cesarean
section, and shoulder dystocia without increasing the risk of small for gestational age.
Nevertheless, the treatment could not reduce the risk of neonatal metabolic abnormalities
or several complications in newborn.Keywords: adverse pregnancy outcome, adversematernal outcomes, adverse neonatal outcomes, mild gestational
diabetes, treatmentINTRODUCTION
Gestational diabetes mellitus (GDM) is defined as diabetes
diagnosed in the second or third trimester of pregnancy
without the presence of overt diabetes prior to gestation (1).
GDM is one of the most common endocrinopathies among
pregnant women and influences 4-12% of all pregnancies (2).
Previous studies have demonstrated that GDM is associated with
the increased risk of adverse feto-maternal and neonatal
outcomes (3, 4). Therefore, its treatment can significantly
reduce both the short- and long-term effects of GDM (5–9).
Lifestyle modifications including diet therapy, physical
exercise, and pharmacological treatments such as oral
antidiabetic medications and/or insulin are suggested for the
treatment of GDM (1). However, there is an ongoing debate
regarding the relationship between various perinatal risk factors
and the milder form of GDM with glucose levels lower than the
criteria for treatment. The Hyperglycemia and Adverse
Pregnancy Outcomes’ (HAPO) study indicated that GDM is
associated with the enhanced risk of adverse perinatal outcomes,
without an obvious threshold at which the risk is increased (10).
Therefore, the determination of an optimal threshold for the
screening and treatment of mild GDM becomes difficult.
Although it has been suggested that mild GDM is associated
with the increased perinatal risk (11–13), it is uncertain whether
the treatment of hyperglycemia exerts a protective influence on
perinatal outcomes among pregnant women with GDM.
Studies on the treatment of mild GDM and its effect on adverse
pregnancy outcomes have shown controversial results. A modest
benefit from the identification and treatment of women with mild
carbohydrate intolerance during pregnancy has been shown (12).
On the other hand, a multicenter randomized trial by Landon et al.
(12) on 958 pregnant women with mild GDM showed that the
treatment of mild GDM did not significantly reduce the frequency
of stillbirth or perinatal death, neonatal hypoglycemia,
hyperbilirubinemia, birth trauma, and elevated cord-blood C-
peptide level. However, it reduced the risk of macrosomia,
shoulder dystocia, cesarean delivery, and pregnancy related
hypertensive disorders (12). In contrast, pharmacological therapy
neither reduced birth weight nor improved maternal or neonatal
outcomes among women with mild GDM (14).n.org 2Given the lack of conclusive evidence regarding the benefits of
the treatment of mild GDM, this systematic review and meta-
analysis investigated the effect of mild GDM treatment on
adverse pregnancy outcomes. Accordingly, the review question
was as follows: does the treatment of mild GDM through diet
therapy and antidiabetic medications improve adverse
pregnancy outcomes in terms of maternal and neonatal
adverse outcomes compared to untreated women?MATERIAL AND METHODS
This systematic review and meta-analysis was informed by the
Preferred Reporting Items for Systematic Reviews and Meta-
Analyses (PRISMA) (15). The review question was framed using
the PICO statement as follows:
P: pregnant women with mild GDM; I: treatment through diet
therapy and medications; C: treatment effect on adverse pregnancy
outcomes; O: maternal and neonatal adverse outcomes.
The objectives of this review were to assess:
o the pooled risk of adverse single and composite maternal
outcomes among those pregnant women who received the
treatment of mild GDM compared to untreated counterparts;
o the pooled risk of adverse single and composite neonatal
outcomes among those pregnant women who received the
treatment of mild GDM compared to untreated counterparts;
o sensitivity analysis based on the exclusion of secondary
analysis studies.Eligibility Criteria
Studies were identified eligible if: (I) they presented a clear
definition of mild GDM or gestational hyperglycemia; (II)
described the details of screening strategies and the threshold
of blood sugar in screening tests; (III) reported at least one of the
short-term single maternal and neonatal outcomes of GDM; (IV)
reported the number or prevalence of adverse events; (V)
described the treatment process; (VI) compared adverse
pregnancy outcomes between those women who received
treatment for mild GDM and untreated counterparts.March 2021 | Volume 12 | Article 640004
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reviews, commentaries, editorials, letters, meeting abstracts,
case reports, and conference proceedings that did not provide
accurate and clear data on research variables, and the presence of
preexisting glucose intolerance or diabetes in studies’ samples.
Search Strategy
A comprehensive literature search was conducted on the
databases of PubMed (including Medline), Web of Science,
and Scopus to retrieve original studies published in English
language and on the prevalence and incidence of adverse
maternal and neonatal outcomes among women with mild
GDM up to May-2020. Further, a manual search in the
references list of the selected studies and other relevant reviews
was carried out to maximize the identification of eligible studies.
The following keywords, alone or in combination using the
Boolean method, were used in the search: (adverse pregnancy
outcomes OR pregnancy outcomes OR pregnancy complications
OR gestational age OR macrosomia OR large for gestational age
OR LGA OR small for gestational age OR SGA OR neonatal
hypoglycemia OR hypoglycemia OR Hyperbilirubinemia OR
icterus OR elevated C-peptide OR c-peptide OR C peptide OR
NICU OR NICU admission OR respiratory distress syndrome
OR RDS OR Apgar OR preterm birth OR preterm labor OR still
birth OR IUFD OR intrauterine fetal death OR mortality OR
IUGR OR intrauterine growth restriction OR polyhydramnios
OR oligohydramnios OR preeclampsia OR pregnancy induced
hypertension OR gestational hypertension OR PIH OR
hemorrhage OR postpartum hemorrhage OR PPH OR placenta
abruption OR decolman OR placenta previa OR antepartum
hemorrhage OR maternal weight gain OR pregnancy weight
gain OR gestational weight gain OR birth weight OR induction
of labor OR labor induction OR induced labor OR instrumental
delivery OR operative delivery OR cesarean sections OR C-section
OR abdominal deliveries OR birth trauma OR shoulder dystocia)
AND (mild gestational diabetes OR mild GDM OR mild
gestational hyperglycemia OR mild maternal hyperglycemia OR
mild glucose intolerance in pregnancy ORmild gestational glucose
intolerance ORmild gestational carbohydrate intolerance ORmild
carbohydrate intolerance in pregnancy OR mild gestational
impaired glucose tolerance OR mild impaired glucose tolerance
in pregnancy).
Study Selection and Data Extraction
The screening of titles, abstracts and full texts of studies was
conducted independently by two authors based on the eligibility
criteria and the following data was extracted from eligible
studies: the first author’s name; journal title; publication year;
country; study design; sample size; population characteristics
including age and body mass index (BMI); mild GDM screening
strategy; mild GDM criteria and laboratory values of blood sugar
tests; treatment details; quality assessment and outcome
measurements including the number and prevalence of adverse
outcomes. To prevent bias in the data extraction and data entry,
the accuracy of data before the meta-analysis was assessed
through double checking the data extraction process.Frontiers in Endocrinology | www.frontiersin.org 3Study Outcomes and Definition of
Mild GDM
For the purpose of the present review, a composite outcome of
adverse maternal outcomes and the important maternal events of
labor induction, cesarean section, preeclampsia was selected.
Also, a composite outcome of adverse neonatal outcomes and
the single neonatal events of macrosomia, large for gestational
age (LGA), small for gestational age (SGA), hypoglycemia,
hyperbilirubinemia, elevated cord C-peptide, admission to the
neonatal intensive care unit (NICU), respiratory distress
syndrome (RDS), shoulder dystopia, and preterm birth was
selected. Mild GDM was defined as any glucose intolerance
during pregnancy, which was lower than the criteria for the
diagnosis of GDM.
Quality Appraisal and Risk of Bias
Quality of the selected studies was critically appraised in terms of
the methodological structure and presentation of results. Two
authors who were blinded to the study’s author and institution,
and the journal’s title evaluated the quality of each study
independently. The modified consolidated standards of
reporting trials (CONSORT) as a validated quality assessment
checklist for RCTs was used for the appraisal. Studies with scores
≥70% of the highest score of the CONSORT checklist were
judged as high quality, 40–70% as moderate quality, 20–40% as
low quality, and <20% as very low quality (16). The risk of bias in
these studies was assessed using the Cochrane Collaboration’s
tool for assessing risk of bias for RCTs (17). Accordingly, the risk
of bias was categorized as ‘low risk’, ‘high risk’, and ‘unclear risk’.
Statistical Analysis
The software package STATA (version 14; STATA Inc., College
Station, TX, USA) was used for statistical data analysis.
Heterogeneity between the studies was assessed using the I2
index and P < 0.05 was interpreted as heterogeneity.
Heterogeneous and non-heterogeneous results were analyzed
using the random/fixed effects models for calculating the
pooled effect, respectively. Publication bias was assessed
through the Harbord test. The DerSimonian and Laird, and
inverse variance methods were used to calculate the pooled odds
ratio (OR, 95% CI) of events. Meta-regression was performed to
explore the effect of maternal age as the source of heterogeneity.
In addition, sensitivity analysis was run to investigate the
influence of each individual study on the overall meta-analysis
summary estimate. A graph of the results of an influence analysis
in which the meta-analysis was re-estimated omitting each study
in turn was presented. P < 0.05 was set as significance level.RESULTS
Search Results, Study Selection, Study
Characteristics, and Quality Assessment
Figure 1 illustrates the flow diagram of the search strategy and
study selection. The search strategy yielded 455 potentiallyMarch 2021 | Volume 12 | Article 640004
Behboudi-Gandevani et al. Mild GDM Treatment and Pregnancy Outcomesrelevant articles, but 53 articles were identified for further full-
text assessment based on the inclusion criteria. Finally, 10 studies
were selected to conduct the meta-analysis consisting of 3317
pregnant women who received treatment for mild GDM, and
4407 untreated counterparts. Table 1 shows a summary of the
studies assessing the risk and prevalence of adverse perinatal
outcomes in the groups.
The quality assessment of the included studies has been
presented in Supplementary Table 1. Five studies were
classified as high quality (12, 18–20, 23), 3 as moderate quality
(14, 21, 25), 2 as low quality (22, 24), but no study had very low
quality. All studies (12, 14, 18–25) had the interventional design,
of which 3 (33.3%) studies were secondary analysis (18–20).
Also, 6 studies were conducted in the USA (12, 14, 18–20, 23),
two in Italy (21, 22), one in Japan (25) and one in Australia (24).
All of studies used glucose tolerance test (GCT)-50 g-1h followed
by oral glucose tolerance test (OGTT)-100 g-3h as the screening
and diagnostic test (12, 14, 18–23, 25), except one that used
OGTT-75 g-2h (24).
Meta-Analysis of Outcomes
Table 2 shows the pooled OR of adverse maternal and neonatal
outcomes, heterogeneity and publication bias estimation in those
women who received the treatment of mild GDM compared to
untreated women.Frontiers in Endocrinology | www.frontiersin.org 4A statistically significant difference between the treatment
group and the control group in the risk of the composite
maternal and neonatal perinatal outcomes was observed
(Pooled OR = 0.8, 95% CI = 0.7-0.9) and (Pooled OR = 0.7,
95% CI = 0.6-0.8), respectively, (Figures 2, 3).
In term of maternal outcomes, the pooled OR of cesarean
section (Pooled OR = 0.8, 95% CI = 0.7-0.9) and shoulder
dystocia (Pooled OR = 0.3, 95% CI = 0.2-0.6) as well as
preeclampsia (Pooled OR = 0.4, 95% CI = 0.3-0.6) were
significantly reduced in the treated group compared with the
untreated group. In contrast, the pooled OR of labor induction
among the treated women was significantly 1.3 folds higher than
that of the untreated women (Pooled OR = 1.3, 95% CI = 1.0-1.6)
(Table 2, Supplementary Figures 1–4).
In terms of neonatal outcomes, the adverse events of SGA,
hypoglycemia, hyperbilirubinemia, birth trauma, admission to the
NICU, and preterm birth were not significantly different between the
groups (Table 2, Supplementary Figures 5–9). However, the risk of
macrosomia (PooledOR= 0.3, 95%CI = 0.3-0.4), LGA (PooledOR=
0.4, 95% CI = 0.3-0.5), elevated cord C-Peptide (Pooled OR = 0.7,
95% CI = 0.6-0.9) and RDS (Pooled OR = 0.7, 95% CI = 0.5-0.9)
among the treated women were significantly lower than that of the
untreated women (Table 2, Figures 4–6, Supplementary Figures 5–
11). According to meta-regression, the reported ORs were not
influenced by maternal age (Supplementary Figure 12).FIGURE 1 | Flow diagram of the search strategy and study selection.March 2021 | Volume 12 | Article 640004
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Since three of the included studies used a secondary analysis design,
sensitivity analysis was performed after their exclusion from the
data analysis process. The results were highly consistent with the
main data analysis’ results (Supplementary Figures 13 A–Q).
Publication Bias and Risk of Bias
No substantial publication bias for meta-analyses based on the
Harbord test was observed (Tables 2). The included studies
mostly were judged as having a low risk of bias for the evaluated
domains (Supplementary Figure 13). Accordingly, all studies
had a low risk of bias in the reporting of selective outcomes andFrontiers in Endocrinology | www.frontiersin.org 5incomplete outcome data, but about 60% of them had an unclear
risk of bias and 20% had a high risk of bias in the blinding of
personnel, participants, and outcome assessment. Also, 10% had
a high risk or unclear risk of bias in random sequence generation
or allocation.DISCUSSION
The results of the current systematic review and meta-analysis
showed that although the treatment of mild GDM did not reduce
the risk of selected neonatal outcomes including hypoglycemia,TABLE 1 | The characteristic of the studies selected for the systematic review and meta-analysis.
Author,
year












FBS< 95 mg/dL and two or more values of
BS-1h >180 mg/dL, BS-2h >155 mg/dL, BS-3h >140
mg/dL
1. with male fetus: n=
244, Age: -, BMI: -
2. with female fetus: n=
233, Age: -, BMI: -
1. with male fetus: n=
225, Age: -, BMI: -
2. with female fetus: n=









1. GCT 50 g-1h, 130-200 mg/dL
2. FBS< 95 mg/dL and two or more values of
BS-1h >180 mg/dL, BS-2h >155 mg/dL, BS-3h >140
mg/dL
2. Hispanic: n= 274,
Age: 29.5 (5.7), BMI:
30.3 (4.4)
2. Non-Hispanic: n=
123, Age: 29.2 (5.9),
BMI: 29.7 (5.5)
1. Hispanic: n= 520,
Age: 27.6 (5.4), BMI:
30.1 (4.5)
1. Non-Hispanic: n=
247, Age: 28 (65.4),
BMI: 29.5 (5.3)
2. Hispanic: n= 225,
Age: 29.5 (5.6), BMI:
30.2 (4.3)
2. Non-Hispanic: n=







USA GCT-50 g -1h
followed by
OGTT-100 g-3h
FBS< 95 mg/dL and two or more values of
BS-1h >180 mg/dL, BS-2h >155 mg/dL, BS-3h >140
mg/dL
1. Normal Weight
Gain: n= 257, Age:
29.5 (5.7), BMI: 25.3
(22.1–28.7)
2. Excessive Weight
Gain: n= 174, Age:
28.8 (5.8), BMI: 26.5
(23.7–29.4)
1. Normal Weight
Gain: n= 188, Age:
29.8 (5.5), BMI: 24.7
(22.3–28.8)
2. Excessive Weight
Gain: n= 222, Age:










1. Only one abnormal value in OGTT 100g: FPG >95
mg/dL or BS-1h > 180 mg/dL or BS-2h > 155 mg/dL
or BS-3h > 140 mg/dL
2. GCT ≥140 mg/dL and OGTT 100g-negative
1. n= 100, Age: 32.9
(4.7), BMI: 25.6 (5.4)
2. n= 350, Age: 31.8









GCT ≥140 mg/dL and OGTT 100g- negative n= 150, Age: 31.1 (4.7),
BMI: 23.1 (4.4)








FBS < 105 mg/dL and at least two elevated values on
BS-1h > 190 mg/dL, BS-2h > 165 mg/dL, BS-3h >
145 mg/dL
n= 189, Age: 31.3 (6),
BMI: 29.0 (4.8)









FBS< 95 mg/dL and two or more values of BS-1h
>180 mg/dL, BS-2h >155 mg/dL, BS-3h >140 mg/dL
n= 264, Age: 29.2 (5.2),
BMI:-







USA GCT-50 g -1h
followed by
OGTT-100 g-3h
FBS< 95 mg/dL and two or more values of BS-1h
>180 mg/dL, BS-2h >155 mg/dL, BS-3h >140 mg/dL
n= 485, Age: 29.2 (5.7),
BMI:-












Japan GCT-50 g -1h
followed by
OGTT-75 g-2h
One elevated value for FBS ≥100 mg/dL, BS-1h ≥ 180
mg/dL, BS-2h ≥ 150 mg/dL
1. n= 172, Age: 34.5
(4.8), BMI: 22.6 (5.3)
2. n= 178, Age: 33.7
(4.7), BMI: 22.7 (4.8)
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preterm birth, it reduced the risks of macrosomia, LGA, elevated
cord C-Peptide and RDS as well as maternal outcomes of
cesarean section, shoulder dystocia and preeclampsia, without
causing any significant increase in the risk of SGA. However, theFrontiers in Endocrinology | www.frontiersin.org 6risk of labor induction among the treated women was higher
than the untreated women.
Despite the unquestionable evidence and the wide range of
recommendations regarding the benefit of treatment for women
with GDM (6, 26, 27), there is an ongoing debate about the effectTABLE 2 | Heterogeneity and publication bias estimation and meta-analysis for the risk of adverse maternal and neonatal outcomes among the treated women with
mild gestational diabetes compared to the untreated women.











10768 8765 0.065 62.7 0.8 (0.7-0.9)
Cesarean section 3497 2829 0.586 0.0 0.8 (0.7, 0.9)
Labor induction 2678 1966 0.652 58.7 1.3 (1.0, 1.6)
Shoulder dystocia 2678 1966 0.881 0.0 0.3 (0.2, 0.6)
Preeclampsia 1729 1815 0.293 0.0 0.4 (0.3, 0.6)
Composite adverse neonatal
outcomes
31510 23322 0.624 62 0.7 (0.6-0.8)
Macrosomia 4299 3265 0.882 0.0 0.3 (0.3, 0.4)
LGA 4873 3609 0.869 43.3 0.4 (0.3, 0.5)
SGA 3788 3259 0.216 0.0 1.1 (0.9, 1.4)
Hypoglycemia 3274 2191 0.484 0.0 1.0 (0.8, 1.2)
Hyperbilirubinemia 3746 2429 0.273 16.8 0.9 (0.7, 1.1)
Elevated cord c-peptide 2180 1850 0.138 32.4 0.7 (0.6, 0.9)
Birth trauma 1096 1141 0.497 0.0 0.5 (0.2, 1.1)
NICU admission 3966 2857 0.273 45.0 0.9 (0.7, 1.2)
RDS 2345 1404 0.348 0.0 0.7 (0.5, 0.9)
Preterm birth 1943 1317 0.749 73.4 0.9 (0.8, 2.4)March 2021 | VolumGDM, Gestational Diabetes; LGA, Large for Gestational Age; SGA, Small for Gestational Age; NICU, neonatal intensive care unit; RDS, Respiratory Distress Syndrome.
*Bold values indicate statistical significance.FIGURE 2 | Forest plot of pooled odds ratio of composite adverse maternal outcome.e 12 | Article 640004
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diagnostic thresholds of GDM. Notably, after the publication
of the results of the HAPO’s study demonstrating that maternal
glycemia continuously was associated with the increasing risk of
adverse perinatal outcomes, with no obvious threshold at which
risks increase, the debate as to whether a benefit exists for the
treatment of the milder form of GDM assumes even greater
importance now than in the past.
Diet therapy along with glucose monitoring was mentioned as
the primary therapeutic choice in all studies meeting our
inclusion criteria for inclusion to our meta-analysis.
Pharmacotherapy and mainly insulin therapy were initiated if
dietary modification failed to control glycemic levels. The
treatment significant decreased the risk of adverse outcomes
related to fetal overgrowth including macrosomia and LGA,
which in turn reduced the risk of shoulder dystocia andFrontiers in Endocrinology | www.frontiersin.org 7caesarean section among the treated women with mild GDM
compared to untreated counterparts. It is suggested that
maternal hyperglycemia therapy can regulate fetal
hyperinsulinemia and subsequently decrease the body
fat storage in fetus (28). It should be noted that although the
treatment increased the risk of SGA as a sign of overtreatment,
the increased risk had no statistically significant difference
between the treated women and the untreated women.
Meanwhile, the risk of induced labor showed a significant
increase in the treatment group compared to the untreated
group. It is hypothesized that knowledge about treatment
allocation may have influenced the decisions of healthcare
providers involved in the study (29). As well, the treatment of
mild GDM decreased the risk of preeclampsia, as a major
complication of pregnancy, in the treated women compared to
the untreated women. This may be due to improvements inFIGURE 3 | Forest plot of pooled odds ratio of composite adverse neonatal outcome.March 2021 | Volume 12 | Article 640004
Behboudi-Gandevani et al. Mild GDM Treatment and Pregnancy Outcomesvascular changes such as arteriosclerosis and glomerular
filtration dysfunction caused by altered carbohydrate
metabolism in the background of insulin resistance (30).
Moreover, our review showed the modest benefit of treatment
in the risk reduction of RDS among the newborns of the treated
women compared to the untreated women. It might be attributed
to the decreased risk of cesarean section and preterm birth in theFrontiers in Endocrinology | www.frontiersin.org 8mild GDM group, but preterm birth showed a non-significant
reduction in the treatment group compared to the
untreated group.
Our review findings showed that treatment significantly
decreased the elevated cord C-peptide as a marker of fetal
hyperinsulinemia (31), but it did not decrease the risk of
metabolic outcomes in newborns. Similarly, we noticed thatFIGURE 4 | Forest plot of pooled odds ratio of small for gestational age.FIGURE 5 | Forest plot of pooled odds ratio of macrosomia.March 2021 | Volume 12 | Article 640004
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adverse neonatal outcomes such as SGA, admission to the NICU
and preterm birth. It can be attributed in part to the fact that
those outcomes are most consistently associated with more
severe glucose intolerance than those that have been present in
the participants included to our study. In this respect, most
participants with mild GDM in our meta-analysis had normal
fasting maternal glucose, but a threshold for an increased risk of
clinical neonatal hypoglycemia might not be apparent until fasting
maternal glucose levels exceeded 100 mg/dL (5.6 mmol/L)
(10, 12).
This is the largest and the most updated systematic review
and meta-analysis of RCTs conducted on the most stringent
method of determining whether a cause-effect relationship exists
between the intervention and outcome. In addition, the included
studies showed consistency across all outcomes of interest and
no statistically significant publication bias was identified.
However, some limitations should be considered during the
interpretation of the results. For instance, given a lack of a
uniform standard for defining mild GDM during pregnancy,
individual studies on the topic has produced a varying definition
for mild GDM, implying that women with different degrees of
glucose intolerance are involved. A lack of unique definition for
each adverse pregnancy outcome might have affected the review
findings. Most of the included studies had a small sample size
and the results were dominated by the secondary analysis of one
study (12). However, for further confirmation and avoidance of
any bias, the sensitivity analysis was performed through
excluding the secondary data. All included studies were
conducted in developed counties and the results might not be
extrapolated to developing countries that might have differencesFrontiers in Endocrinology | www.frontiersin.org 9in the lifestyle and healthcare standards. Also, the ethnicity as the
source of heterogenicity could not be assessed given the lack of
related information in the studies. Moreover, subgroup-analysis
based on the results of fasting maternal glucose, as an important
indicator of adverse pregnant outcomes, could not be performed
(10), because defined mild GDM criteria in the studies mostly
had normal fasting blood sugar. Since most of the studies used
diet therapy and/or insulin therapy, the effect of various
treatments of mild GDM on adverse pregnancy outcomes
between the groups could not be compared. We could not
achieve enough power to report significant results for some
outcomes including perinatal/neonatal mortality and
intrauterine fetal death.
In conclusion, the treatment of mild GDM using diet therapy
and insulin is likely to reduce the risk of several key adverse
outcomes of interest such as macrosomia and LGA, shoulder
dystocia, cesarean section, preeclampsia as well as newborn RDS,
without causing any significant increase in the risk of SGA. Also,
our review findings indicated that the treatment of mild GDM
might not reduce other adverse neonatal outcomes. Further
studies with larger sample sizes are required in different
population and ethnicities to examine the effect of treatment
on other important adverse pregnancy outcomes with
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